Common Stock, par value $0.0001 per share
- Symbol
- RNAZ
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 7.01, 9.01 · 8-K
TransCode Therapeutics, Inc.
RNAZNASDAQEQUITYCurrent
Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On January 6, 2026, TransCode Therapeutics, Inc. (“TransCode”) issued a press release announcing the publication of preclinical research regarding the application of its lead candidate, TTX-MC138, for the treatment of glioblastoma multiforme. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.…
Company context
TransCode is a clinical-stage company pioneering immuno-oncology and RNA therapeutics for treatment of high risk and advanced cancers We possess a diversified pipeline of therapeutic candidates, including two clinical stage assets, TTX-MC138, an antisense inhibitor of an oncogenic microRNA and Seviprotimut-L, a cancer vaccine. We also possess an oncolytic immunotherapy platform and three TTX-based pre-clinical stage assets.
Current securities
Recent company filings
- Other EventsOct 28, 2026
- Entry into a Material Definitive Agreement · Triggering Events That Accelerate or Increase a Direct Financial ObligationOct 1, 2026
- Other EventsSep 28, 2026
- 3 filingSep 21, 2026
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsSep 11, 2026
Registered securities in this filing
TRANSCODE THERAPEUTICS, INC. · 8-K · Filed 2026-01-06
Disclosure sections
Item 7.01Item 7.01 - Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.
On January 6, 2026, TransCode Therapeutics, Inc.
(“TransCode”) issued a press release announcing the publication of preclinical research regarding the application of its lead
candidate, TTX-MC138, for the treatment of glioblastoma multiforme. A copy of this press release is furnished as Exhibit 99.1 to this
Current Report on Form 8-K.
The information in this Item 7.01, including Exhibit
99.1 hereto, is being furnished herewith and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange
Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed
incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange
Act, except as expressly set forth by specific reference in such a filing.
Filed exhibits (1)
Exhibit 99.1 TransCode Therapeutics Announces Publication of Preclinical Data Supporting Therapeutic Potential of TTX-MC138 in Glioblastoma · TTX-MC138 is delivered to glioblastoma tumors in murine models of the disease, following intravenous injection · TTX-MC138 demonstrated suppression of miR-10b target and extended survival in aggressive glioblastoma models · Study supports future clinical development of TTX-MC138 for patients with glioblastoma BOSTON, January 6, 2026 - TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancer, today announced the publication of preclinical research supporting the application of its lead candidate, TTX-MC138, for the treatment of glioblastoma multiforme (GBM). The article was published in the peer-reviewed Journal of Functional Biomaterials (Volume 17, Issue 1). The study, entitled “Nanotherapy Targeting miR-10b Improves Survival in Orthotopic Glioblastoma Models,” resulted from a collaboration between TransCode and Michigan State University. The study was led by Dr. Anna Moore, Professor, Director of the Precision Health Program,…
Open exhibit ↗